Added to YB: 2026-09-11
Pitch date: 2026-09-09
ZNTL [neutral]
Zentalis Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Market Cap
$359.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.54
P/E
-1.94
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Wells Fargo Healthcare Conference Biotech day 1 Batch 3 - Zentalis Pharmaceuticals — ZNTL 70/64
ZNTL (quick overview): Zentalis is advancing oral WEE1 inhibitor azenosertib for Cyclin E1-high platinum-resistant ovarian cancer, estimated at roughly 50% of that population. Denali Part 2 data are expected in the first half of 2027, with the company targeting an overall response rate of approximately 30% or greater and duration of response around five months or longer. The pivotal thesis depends on durable responses, reliable biomarker selection and acceptable safety after an FDA partial clinical hold following treatment-related deaths.
Read full article (1 min)